

**EUROPEAN
CURRICULUM VITAE**



PERSONAL INFORMATION

Name ALESSANDRO BUDA

country ITALY

Born date 28/07/1972

JOB EXPERIENCES

- Date (from – to) 12/05 to date
MD Gynecologist at the Division of Gynecology and Obstetrics at San Gerardo Hospital, Monza, Milan (Italy)
- hospital SAN GERARDO HOSPITAL, UNIVERSITY OF MILANO-BICOCCA, MONZA, MILAN
- degree MD
- main field of activity SPECIALIST IN ONCOLOGICAL SURGERY AND PELVIC SURGERY, MININVASIVE LAPAROSCOPIC SURGERY (ONCOLOGICAL AND BENIGN GYNECOLOGICAL DISEASE) WITH MORE THAN 1000 PROCEDURES PERFORMED FROM 2004 (OPEN SURGERY, LAPAROSCOPIC AND VAGINALLY)

CERTIFICATIONS

- Date (from – to) 1999
Medical Doctor at the University of Milan with the tesi entitled: prognostic significance of the expression of phosphatase CDC25A, B and C in advanced ovarian cancer.

Spring-summer 1997
Researcher at The Laboratory of Biomolecular Epidemiology (Center for Nutrition and Toxicology, Department of Bioscience NOVUM), Karolinska University-Stockholm – ERASMUS project award

From 1998 to date
Collaboration on gynecological oncologic project and research with the Laboratory of Clinical Oncological Research at the “Mario Negri” Institute of Milan

12/2005
Gynecologist degree at the University of Milano-Bicocca with the thesis entitled: the Role of pathological response as early indicator of efficacy in neoadjuvant chemotherapy to radical surgery in locally advanced cervical cancer.

FIRST LANGUAGE **ITALIAN**

OTHERS

ENGLISH,SPANISH

SOFTWARE ABILITY WELL KNOWN PROGRAMS OF WINDOWS OFFICE E MAC;
Internet Explorer, WORD, P.POINT,ACCESS, EXCEL,SAS system version 6.12

DRIVE LICENCE TYPE B

OTHER INFORMATIONS ESGO Member 2010-2011-2012; ESGE member 2010-2011; SIOG member 2012

FILE ENCLOSED PUBBLICATIONS

Monza, February 2012

signature

ALESSANDRO BUDA

International major publications

1) E Mari, I Floriani, A Tinazzi, **A Buda**, et al.

Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials.

Ann Oncol 11: 837-843, 2000

2) The ICON Collaborators (**A Buda**, name listed in ICON group)

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

The Lancet, 360: 505-515, 2002

3) MG Cantù, **A Buda**, G Parma, et al.

Randomised controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.

J Clin Oncol, 20 (5): 1232-1237, 2002

4) G Zanetta, S Rota, A Lissoni, A Meni, G Brancatelli and **A Buda**

Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors

Gynecol Oncol, 81: 63-66-2001

5) ICON1 and EORTC-ACTION collaborators (**Alessandro Buda**, name listed in ICON office Mario Negri Institute, Italy).

International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma

J Natl Cancer Inst 2003; 95: 105-112

6) ICON1 collaborators (**A Buda**, name listed in ICON office Mario Negri Institute, Italy)

International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer

J Natl Cancer Inst 2003; 95: 125-132

7) **Buda A**, Dell'Anna T, Signorelli M and Mangioni C

Role of ifosfamide in cervical cancer. an overview

Oncol, 65 (suppl. 2): 63-66, 2003

8) Manenti L, Paganoni P, Floriani I, Torri V, **Buda A**, Landoni F, Taraboletti G, Belotti D, Giavazzi R.

Expression level of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in plasma of patients with ovarian carcinoma.

Eur J Cancer, 39: 1948-1956, 2003

9) Torri V, Floriani I, Poli D, Santillo M, **Buda A**

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

Lancet , 361: 2099-2106 (362: 1504, 2003)

10) **Buda A**, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, Fossati R, Ravaioli A, Mangioni C.

Randomised controlled trial comparing single agent paclitaxel versus epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the "Mario Negri" Institute, Milan, GONO (Gruppo Oncologico Nord Ovest) group and IOR (Istituto Oncologico Romagnolo) group.

Br J Cancer, 90: 2112-2117, 2004

11) G Apolone, **A Buda**.

Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality of life evaluation?

Ann Oncol, 15(9):1443-4, 2004

12) G Cavaletti, G Bogliun, L Marzorati, A Zincone, M Piatti, N Colombo, D Franchi, MT La Presa, A Lissoni, **A Buda**, F Fei, S Cundari, C Zanna.

Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy.

Ann Oncol. 15(9):1439-42, 2004.

13) Bonazzi C, Urso M, Dell'Anna T, Sacco S, **Buda A**, Cantu MG.

Placental site trophoblastic tumor: an overview.

J Reprod Med, 49(8):585-588, 2004

14) **A Buda**, R Fossati, N Colombo et al.

Randomized Trial of Neoadjuvant Chemotherapy Comparing a Three-Drug Combination of Paclitaxel, Ifosfamide, and Cisplatin Versus Ifosfamide and Cisplatin Followed by Radical Surgery in Patients With Locally Advanced Squamous Cell Cervical Carcinoma: The SNAP01 Italian Collaborative Study

J Clin Oncol, 23: 4137-4145 , 2005

15) S Sironi , **A Buda**, M Picchio, et al.

Lymph node metastasis in patients with clinical early stage cervical cancer: detection with integrated FDG PET/CT

Radiology 238 (1): 272-279, 2006

16) **A Buda**, L Ferrari, C Marra et al.

Vulvar endometriosis in surgical scar after excision of the Bartholin gland: report of a case.

Arch Gynecol Obstet 277 (3): 255-6, 2007

17) **A Buda**, G Pizzocaro, P Ceruti et al.

Case report: renal cell carcinoma presentino as hypertension in pregnancy.

Arch Gynecol Obstet 277 (3): 263-5, 2007

18) Lissoni AA, Colombo N, Pellegrino A, Parma G, Zola P, Katsaros D, Chiari S, **Buda A**, Landoni F, Peiretti M, Dell'anna T, Fruscio R, Signorelli M, Grassi R, Floriani I, Fossati R, Torri V, Rulli E.

A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study.

Ann Oncol. 2009 Jan 30 ([Epub ahead of print]

19) Pellegrino A, Signorelli M, Fruscio R, Villa A, **Buda A**, Beretta P, Garbi A, Vitobello D.

Feasibility and morbidity of total laparoscopic radical hysterectomy with or without pelvic lymphadenectomy in obese women with stage I endometrial cancer.

Arch Gynecol Obstet. 2008 Sep 16. [Epub ahead of print]

20) A. A. Lissoni, N. Colombo, A. Pellegrino, G. Parma, P. Zola, D. Katsaros, S. Chiari, **A. Buda** et al.

A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study

Ann Oncol. 2009 Apr;20(4):660-5. Epub 2009 Jan 30.

21) **Buda A**, Pellegrino A, Vitobello D, Meroni MG, Recalcati D, Perego P.

Total laparoscopic radical parametrectomy, partial colpectomy, and pelvic lymphadenectomy in patients with occult cervical cancer.

Int J Gynaecol Obstet. 2009 Oct;107(1):73-6. Epub 2009 Jun 24.

22) Signorelli M, Guerra L, **Buda A**, Picchio M, Mangili G, Dell'Anna T, Sironi S, Messa C.

Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases.

Gynecol Oncol. 2009 Nov;115(2):231-5. Epub 2009 Aug 19.

23) Signorelli M, Fruscio R, Dell'Anna T, **Buda A**, Giuliani D, Ceppi L, Milani R.

Lymphadenectomy in uterine low-grade endometrial stromal sarcoma: an analysis of 19 cases and a literature review.

Int J Gynecol Cancer. 2010 Nov;20(8):1363-6.22)

24) Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, **Buda A**, Romualdi C, D'Incalci M.

Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.

Lancet Oncol. 2011 Mar;12(3):273-85. Epub 2011 Feb 21

25) Signorelli M, Guerra L, Montanelli L, Crivellaro C, **Buda A**, Dell'Anna T, Picchio M, Milani R, Fruscio R, Messa C

Preoperative staging of cervical cancer: is 18-FDG-PET/CT really effective in patients with early stage disease?

Gynecol Oncol. 2011 Nov;123(2):236-40. Epub 2011 Aug 19.

26) Misani M, Rovati LC, Confalonieri P, **Buda A**, Giuliani D, Del Bene M.

Modified lotus petal flap for vulvo-vaginal reconstruction after resection for vulvar cancer: a single institution experience.

Handchir Mikrochir Plast Chir. 2011 Aug;43(4):250-4.

27) **Buda A**, Giuliani D, Montano N, Perego P, Milani R.

Primary insular carcinoid of the ovary with carcinoid heart disease: unfavorable outcome of a case.

International Journal of Surgery Case Reports 2012; 3(2): 59-61.

28) **Alessandro Buda**, Pier Luigi Confalonieri, Luca Carlo Vittorio Rovati, Robert Fruscio, Daniela Giuliani, Mauro Signorelli, Tiziana Dell'Anna, Cecilia Pirovano, Rodolfo Milani

Better anatomical and cosmetic results using tunnelled lotus petal flap for plastic reconstruction after demolitive surgery for vulvar malignancy.

Int J Gynecol Cancer 2012; 22 (5): 860-4

29) **A Buda**, R Fruscio, C Pirovano, M Signorelli, M Betti, R Milani.

TachoSil patch for the prevention of postoperative complications after groin dissection in gynecological malignancy.

Int J Obstet Gynecol 2012; 117 (3): 217-9

30) **Alessandro Buda**, Federica Elisei, Maurizio Arosio, Carlotta Dolci, Mauro Signorelli, Patrizia Perego, Daniela Giuliani, Dario Recalcati, Giorgio Cattoretti, Rodolfo Milani, Cristina Messa

Integration of hybrid SPECT/CT in the preoperative assessment of sentinel node in patients with uterine cancer: our experience and literature review.

Int J Gynecol Cancer 2012; 22 (5): 830-5

31) **Buda A**, Confalonieri PL, Rovati LC, Signorelli M, Del Bene M.

Tunneled modified lotus petal flap for surgical reconstruction of severe introital stenosis after radical vulvectomy.

Int J Surg Case Rep. 2012;3(7):299-301.

32) Caiola E, Rulli E, Fruscio R, **Buda A**, Brogginini M, Marabese M.

KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.

Am J Cancer Res. 2012;2(3):298-308.

33) Crivellaro C, Signorelli M, Guerra L, De Ponti E, **Buda A**, Dolci C, Pirovano C, Todde S, Fruscio R, Messa C.

18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer.

Gynecol Oncol. 2012 Jul 5. [Epub ahead of print]

Medical book and collaborations

1) F Landoni, F Vecchione, T Dell'Anna, C Mangioni, C Bonazzi, **A Buda**, M Zoccatelli.

I tumori dell'ovaio.

In Trattato di Chirurgia Oncologica, Capitolo 74; Vol III. Ed. Piccin 2002.

2) Clinical Evidence: Translation CE FULL TEXT chapters on women health

In Clinical Evidence, Italian Edition, 3, 2005 (edizione integrale online: <http://aifa.clinev.it>)

3) Clinical Evidence: Translation CE FULL TEXT chapters on women health

In Clinical Evidence, Italian Edition, 4, 2006 (edizione integrale online: <http://aifa.clinev.it>)

4) DVD entitled: totally laparoscopic radical hysterectomy with pelvic lymphadenectomy.

Pellegrino A, Vitobello D, Meroni M, N Iedà, **A Buda**. Istituto di scienze Biomediche, Università degli Studi Milano-Bicocca, San Gerardo dei Tintori Monza, Clinica di Ostetricia e Ginecologia

In collaborazione con AB Medica, Cooper Surgical, Gyrus Acmi, Taut, Vims, 2007